利司那肽:一种独特的短效胰高糖素样肽-1受体激动剂  

Lixisenatide: A Novel Short-acting Glucagon-like Peptide-1 Receptor Agonist

作　　者：母义明[1] MU Yi-ming(Department of Endocrinology, Peoples Liberation Army General Hospital, Beijing 100853, china)

机构地区：[1]中国人民解放军总医院内分泌科,北京100853

出　　处：《药品评价》2017年第15期8-13,共6页Drug Evaluation

摘　　要：利司那肽是一天一次给药的短效胰高糖素样肽-1(GLP-1)受体激动剂。作为一种独特的短效GLP-1受体激动剂,其延缓胃排空降低餐后血糖的作用显著,但对胰岛素分泌的作用较弱,甚至可节约餐后胰岛素的分泌。无论单用,与口服降糖药(OADs)亦或与基础胰岛素联用,利司那肽均能显著降低糖化血红蛋白(HbA_(1c))、餐后血糖(PPG)和空腹血糖(FPG)水平,尤其以PPG降低最为显著。本药低血糖风险小,可减轻体重,耐受性良好,部分患者虽有胃肠道不良反应,但其发生率会随治疗时间延长而逐渐降低。这也使得利司那肽在2型糖尿病个体化治疗中具有广阔的应用前景。Lixisenatide is a novel once-daily GLP-1receptor agonist(GLP-1RA)with more pronounced effect on PPG by slowing gastric emptyingrather than stimulating insulin secretion.The efficacy of lixisenatide has been proved when used monotherapy and as adjunctive therapy to both OADsand basal insulin by significantly reducing the glycated hemoglobin(HbA1c),fasting plasma glycaemia(FPG)and PPG levels in T2DM patients.Besides,the incidence of hypoglycaemia with lixisenatide is low;and improvements in glycemic control with lixisenatide are coupled with reductionsin body weight.Furthermore,the once-daily dose of lixisenatide is well tolerated.As a result,lixisenatide regimens have broadened treatment choicesfor individualized T2DM management.

关 键 词：GLP-1受体激动剂 餐后血糖 利司那肽 个体化治疗 

分 类 号：R977.15[医药卫生—药品]